SUBJECT TO COMPLETION, DATED JULY 15, 2019
Preliminary Prospectus Supplement
(to Prospectus dated
April 29, 2019)
REPLIGEN CORPORATION
$250,000,000
% Convertible Senior Notes due 2024
We are offering $250,000,000 principal amount of our % Convertible Senior Notes due 2024, or the notes. The notes will
bear interest at a rate of % per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The notes will mature on July 15, 2024, unless earlier
converted or repurchased.
Holders may convert their notes at their option at any time prior to the close of business on the business day
immediately preceding April 15, 2024 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2019 (and only during such calendar quarter), if the last
reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is
greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period, or the measurement period, in which the trading price (as
defined in this prospectus supplement) per $1,000 principal amount of notes, as determined following a request by a holder of notes in accordance with the procedures described herein, for each trading day of the measurement period was less than 98%
of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after April 15, 2024 until the close of business on the
second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their notes at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash,
shares of our common stock or a combination of cash and shares of our common stock, at our election, as described in this prospectus supplement.
The conversion rate will initially be shares of common stock per $1,000 principal amount of
notes (equivalent to an initial conversion price of approximately $ per share of common stock). The conversion rate will be subject to adjustment upon the occurrence of certain events but will not be
adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in
connection with such a corporate event.
We may not redeem the notes prior to the maturity date, and no sinking fund is provided for the
notes.
If we undergo a fundamental change (as defined in this prospectus supplement), holders may require us to repurchase for cash all or
any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.
The notes will be our senior unsecured obligations and will rank senior in right of payment to all of our indebtedness that is expressly
subordinated in right of payment to the notes; equal in right of payment to any of our unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the
assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities of our current or future subsidiaries (including trade payables).
Concurrently with this offering of notes, we are offering $100 million of our common stock (or $115 million of our common stock if the
underwriters in that offering exercise their option to purchase additional shares in full) in an underwritten offering pursuant to a separate prospectus supplement, or the Concurrent Common Stock Offering. Assuming an offering price of $85.00 per
share, the last reported sale price of our common stock on the Nasdaq Global Select Market on July 12, 2019, we expect to offer 1,176,470 shares of common stock in the Concurrent Common Stock Offering. The closing of this offering of notes is
not conditioned upon the closing of the Concurrent Common Stock Offering and the closing of the Concurrent Common Stock Offering is not conditioned upon the closing of this offering of notes. This prospectus supplement is not an offer to sell or a
solicitation of an offer to buy any securities being offered in the Concurrent Common Stock Offering.
We do not intend to apply to list the
notes on any securities exchange or any automated dealer quotation system. Our common stock is listed on the Nasdaq Global Select Market under the symbol RGEN. The last reported sale price of our common stock on the Nasdaq Global Select
Market on July 12, 2019 was $85.00 per share.
|
|
|
|
|
|
|
|
|
|
|
Per
Note
|
|
|
Total
|
|
Public offering price
(1)
|
|
$
|
|
|
|
$
|
|
|
Underwriting discounts and
commissions
(2)
|
|
$
|
|
|
|
$
|
|
|
Proceeds to Repligen Corporation, before expenses
|
|
$
|
|
|
|
$
|
|
|
(1)
|
Plus accrued interest, if any, from July , 2019.
|
(2)
|
We have agreed to reimburse the underwriters for certain expenses. See Underwriting.
|
Investing in the notes involves a high degree of risk. See
Risk Factors
beginning on page
S-23
of this prospectus supplement, in our Annual Report on Form
10-K
for the year ended December 31, 2018 and in our Quarterly Report on Form
10-Q
for the quarter ended March 31, 2019, which are incorporated herein by reference.
We have
granted the underwriters an option to purchase, within a
13-day
period from, and including, the initial issuance date of the notes, up to an additional $37,500,000 principal amount of additional notes from us
at the public offering price, less underwriting discounts and commissions, solely to cover over-allotments, if any.
Neither the Securities and Exchange
Commission (the SEC) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the
contrary is a criminal offense.
We expect that delivery of the notes will be made to investors in book-entry form through the
Depository Trust Company on or about July , 2019.
Sole
Book-Running Manager
J.P. Morgan
The date of
this prospectus supplement is July , 2019.